Rhythm Pharmaceuticals, Inc.
NASDAQ•RYTM
CEO: Dr. David P. Meeker M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2017-10-09
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
連絡先情報
時価総額
$6.24B
PER (TTM)
-31.8
18.8
配当利回り
--
52週高値
$122.20
52週安値
$45.91
52週レンジ
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$57.25M+0.00%
直近4四半期の推移
EPS
-$0.73+0.00%
直近4四半期の推移
フリーCF
-$26.34M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Strong Product Revenue Growth Product revenue reached $194.8M USD in 2025, marking a 50% increase over 2024 sales figures.
R&D Spending Decreased Research and development expenses fell $70.6M USD, down 30% from 2024, due to IPR&D cost non-recurrence.
Operating Loss Significantly Reduced Loss from operations improved $73.5M USD, down 28% to a $192.0M USD loss for 2025.
Pipeline Advancement Milestones Setmelanotide AHO PDUFA date set for March 20, 2026; EMANATE Phase 3 data expected early 2026.
リスク要因
Limited Operating History Risks Commercial stage company anticipates continued losses; profitability remains uncertain despite $422.5M lifetime product sales.
Capital Raising Uncertainty Additional funding required; failure to secure necessary capital may delay or terminate product development efforts.
Reimbursement Coverage Limits Revenue IMCIVREE commercial success depends on payor coverage; failure to secure reimbursement severely limits revenue generation potential.
Early Trial Results Not Predictive Positive results from early setmelanotide trials may not predict later trial outcomes or regulatory success for new indications.
見通し
Acquired HO Market Launch Anticipate launching IMCIVREE for acquired hypothalamic obesity in US during 2026, pending regulatory approval.
Bivamelagon Phase 3 Planning Plan to initiate Phase 3 registrational trial for bivamelagon in acquired hypothalamic obesity by year-end 2026.
CHI Candidate Nomination Focused on identifying and nominating a development candidate for Congenital Hyperinsulinism (CHI) program in 2026.
Japan Regulatory Submissions Expect to complete new drug application submission in Japan pending positive Phase 3 Japanese cohort data in March 2026.
同業比較
売上高 (TTM)
$677.56M
$262.60M
$205.63M
粗利益率 (最新四半期)
102.3%
94.9%
92.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| RVMD | $19.50B | -16.5 | -63.1% | 6.7% |
| NUVL | $7.23B | -17.6 | -42.1% | 0.0% |
| ACLX | $6.69B | -28.1 | -55.4% | 15.9% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
20.5%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月5日
EPS:-$0.78
|売上高:$58.03M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし